Table 3.

Cox proportional-hazards regression model for OS and DFS in patients with stage IB lung ADC in the primary cohort.

Variables	STAS-negative						STAS-positive
	OS			DFS			OS			DFS
	Univariate analysis	Multivariate analysis		Univariate analysis	Multivariate analysis		Univariate analysis	Multivariate analysis		Univariate analysis	Multivariate analysis
	p	HR (95% CI)	p	p	HR (95% CI)	p	p	HR (95% CI)	p	p	HR (95% CI)	p
Histologic Pattern	<0.001		<0.001	<0.001		<0.001	0.001		0.017	<0.001		0.003
Lepidic predominant		0.375 (0.196–0.720)	0.003		0.389 (0.201–0.751)	0.005		0.784 (0.409–1.503)	0.464		0.816 (0.431–1.545)	0.533
Acinar predominant		0.421 (0.234–0.756)	0.004		0.432 (0.239–0.780)	0.005		0.825 (0.446–1.523)	0.538		0.831 (0.443–1.558)	0.563
Papillary predominant		0.260 (0.117–0.577)	0.001		0.750 (0.426–1.321)	0.319		0.940 (0.507–1.741)	0.844		0.945 (0.506–1.766)	0.859
Micropapillary predominant		1.607 (0.993–2.600)	0.053		1.870 (1.154–3.030)	0.011		1.831 (1.039–3.228)	0.037		2.044 (1.157–3.609)	0.014
Solid predominant		1			1			1			1
Surgical Procedure (Lob versus Sublobar)	<0.001	0.482 (0.340–0.685)	<0.001	<0.001	0.588 (0.422–0.819)	0.002	<0.001	0.476 (0.323–0.702)	<0.001	<0.001	0.468 (0.319–0.688)	<0.001
Adjuvant Chemotherapy (with versus without)	0.002	0.559 (0.368–0.850)	0.006	<0.001	0.463 (0.309–0.693)	<0.001	0.042	0.604 (0.397–0.919)	0.018	0.016	0.565 (0.372–0.858)	0.007

ADC, adenocarcinoma; CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; OS, overall survival; STAS, spread through air spaces.